Evaluation of the content of interleukin-31 in serum of patients with severe psoriasis
Abstract
The article provides a brief overview of fhe immunological concept of fhe development of the inflammatory process in psoriasis, presently known facts abouf fhe participation of pro-inflammafory and anfi-in-flammafory cytokines in if. The issue of fhe absence in fhe literature of data on fhe participation of IL-31 in fhe pathogenesis of pruritus in psoriasis is touched upon. The results of studying fhe level of IL-31 in fhe serum of pafienfs wifh severe forms of psoriasis are presented.
About the Authors
I. M. Korsunskaya
Centre for Theoretical Problems of Physicochemical Pharmacology
Russian Federation
Russian Federation
O. O. Melnichenko
Moscow Scientific and Practical Centre for Dermatovenereology and Cosmetology
Russian Federation
Russian Federation
References
1. Torres T, Sales R, Vasconcelos C, Selores M. Psoriasis and Cardiovascular Disease // Acta Med Port. 2013 Sep-Oct; 26 (5): 601-607.
2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence // J Invest Dermatol. 2013 Feb; 133 (2): 377-85.
3. De Oliveira M de FSP, Rocha B de O, Duarte GV. Psoriasis: classical and emerging comorbidities // Anais Brasileiros de Dermatologia 2015; 90 (1): 9-20.
4. О. О. Мельниченко, Н. В. Качанова, А. Ю. Васильева, Е. Н. Маляренко, О. В. Жукова, И. М. Корсунская. Опыт комплексной фармакотерапии псориаза в сочетании с плазмаферезом. // Клиническая дерматология и венерология. № 4, 2016, с. 102-107.
5. Roh NK, Han SH, Youn HJ, Kim YR, Lee YW, Choe YB, Ahn KJ. Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison between Plaque and Guttate Psoriasis//Ann Dermatol. 2015 Dec; 27 (6): 738-743.
6. Zhao Y., Zhang Y, Wang F., Wu H., Luo Z., Luo D., Chen W. Developing Shingles-Induced Koebner Phenomenon in a Patient With Psoriasis // Medicine (Baltimore). 2015 Jul; 94 (26): e1009.
7. Nickoloff B. J., Nestle F. O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities // J Clin Invest. 2004 Jun; 113 (12): 1664-1675.
8. Караулов А. В., Быков С. А., Быков А. С. Иммунология, микробиология и иммунопатология кожи.- М.: Издательство БИНОМ, 2012-328 стр.: 15-251.
9. Lee E, Zarei M, LaSenna C, Villada G, Romanelli P. Psoriasis Targeted Therapy: Characterization of Interleukin 17A Expression in Subtypes of Psoriasis // J Drugs Dermatol. 2015 Oct; 14 (10): 1133-6.
10. Chhabra S, Narang T, Joshi N, Goel S, Sawatkar G, Saikia B, Dogra S, Bansal F, Minz R. Circulating T-helper 17 cells and associated cytokines in psoriasis // Clin Exp Dermatol. 2016 Oct; 41 (7): 806-10.
11. Соболев В. В., Стародубцева Н.Л., Соболева А. Г., Рахимова О. Ю., Корсунская И. М., Пирузян. Э.С., Миннибаев М. Т., Кривощапов Л., Брускин С. А., Воронько О. Е. Роль интерлейкинов в патогенезе псориаза // Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2010. Т. 5. № 12. стр. 79-84.
12. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B. IL-31: a new link between T cells and pruritus in atopic skin inflammation // J Allergy Clin Immunol. 2006; 117 (2): 411-7.
13. Park K, Mori T, Nakamura M, Tokura Y. Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo // Eur J Dermatol. 2011 Jan-Feb; 21 (1): 135-6.
14. Welz-Kubiak K, Kobuszewska A, Reich A. IL-31 is overexpressed in lichen planus but its level does not correlate with pruritus severity // J Immunol Res. 2015; 2015: 854747.
15. Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, Loren AW, Dentchev T, Wysocka M, Yosipovitch G, Rook AH. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus // J Invest Dermatol. 2013; 133 (12): 2783-5.
16. Rabenhorst A., Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases // Curr Allergy Asthma Rep. 2014 Apr; 14 (4): 423.
17. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus // Arch Dermatol Res. 2011 Jan; 303 (1): 1-10.
18. Соколова Т. В., Федоровская Р. Ф., Ланге А. Б. Чесотка. М.: Медицина, 1989.
19. Потекаев Н. С., Потекаев Н. Н., Львов А. Н. Распознавание болезней кожи. М.: Группа МДВ, 2016.- 120 с., ил.: 28-29.
Review
For citations:
Korsunskaya I.M., Melnichenko O.O. Evaluation of the content of interleukin-31 in serum of patients with severe psoriasis. Medical alphabet. 2018;2(31):9-11. (In Russ.)
Views:
426
Email this article 